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Abstract 
 
Dysregulation of neuropeptides may play an important role in aging-induced impairments. 
Among them, pituitary adenylate cyclase activating polypeptide (PACAP) is a potent 
cytoprotective peptide that provides an endogenous control against a variety of tissue-damaging 
stimuli. We hypothesized that the progressive decline of PACAP throughout life, and the well-
known general cytoprotective effects of PACAP lead to age-related pathophysiological changes 
in PACAP deficiency, supported by the increased vulnerability to various stressors of animals 
partially or totally lacking PACAP. Using young and aging CD1 PACAP knockout (KO) and 
wild type (WT) mice, we demonstrated pre-senile amyloidosis in young PACAP KO animals 
and showed that senile amyloidosis appeared accelerated, more generalized, more severe, and 
affected more individuals. Histopathology showed age-related systemic amyloidosis with 
mainly kidney, spleen, liver, skin, thyroid, intestinal, tracheal and esophageal involvement. 
Mass spectrometry-based proteomic analysis, re-confirmed with immunohistochemistry, 
revealed that apolipoprotein-AIV was the main amyloid protein in the deposits together with 
several accompanying proteins. Although the local amyloidogenic protein expression was 
disturbed in KO animals, no difference was found in laboratory lipid parameters, suggesting a 
complex pathway leading to increased age-related degeneration with amyloid deposit in the 
absence of PACAP. In spite of no marked inflammatory histological changes or blood test 
parameters, we detected a disturbed cytokine profile that possibly creates a pro-inflammatory 
milieu favoring amyloid deposition. In summary, here we describe accelerated systemic senile 
amyloidosis in PACAP gene deficient mice, which might indicate an early aging phenomenon in 
this mouse strain. Thus, PACAP KO mice could serve as a model of accelerated aging with 
human relevance. 
 
Key words: amyloid, apolipoprotein-AIV, MALDI Imaging, proteomic analysis 
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Introduction 
 
Previous findings indicate that PACAP progressively declines during aging and its deficiency 
substantially increases tissue vulnerability[1,2]. Here we hypothesize that PACAP deficiency 
leads to age-related systemic degeneration, causing accelerated pre-senile systemic amyloidosis, 
as a representation of the aging-related chronic condition (physiological as well as disease-
related) in mice.  
Amyloidosis is a heterogeneous group of diseases, from small local to generalized 
systemic forms, characterized by the deposition of amyloid fibrils caused by inappropriate 
protein aggregation [3-7]. Many forms affect the brain (such as Alzheimer’s and Parkinson’s 
disease), while others leave the CNS intact [3,8]. Advances in proteomics have revealed more 
than 30 different proteins prone to fibril formation in the complex amyloid matrix [6,9-13]. 
Excessive production, mutations or proteolytic digestion can result in an amyloidogenic protein 
form, the fibril formation of which requires several factors, such as proteases, nucleating 
particles, chaperons, matrix molecules and microenvironment[10,13] the balance of which can 
be disturbed in aging, when senile amyloidosis occurs in several mouse strains as well as in 
humans[8].  
 Natural peptides or peptide-based molecules preventing amyloid formation or its 
progression have been recognized [3,14] as molecules with possible interference in 
amyloidogenic mechanisms including stabilizing non-toxic amyloid species, redirecting 
aggregation pathways, trapping toxic amyloid species or retaining native protein conformation 
[15]. In turn, dysregulation of neuropeptides may play a role in aging-induced impairments and 
accelerate formation of amyloid deposits [16]. PACAP is a highly effective neuro- and general-
cytoprotective peptide that provides an endogenous control in tissue damage by exerting a 
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unique combination of simultaneous promotion of anti-inflammatory, anti-apoptotic and anti-
oxidant pathways mainly via PAC1 receptor and VPAC1/2 receptors [1,2,17-21]. 
PACAP decline has been reported in aging human and monkey brains [22,23] and in 
aging rat cerebrovascular cells, where decreased release of endothelial PACAP upon oxidative 
stress can be observed [24,25]. Lack of endogenous PACAP results in a variety of 
abnormalities[2,18], for example, lower level or absence of PACAP leads to increased 
vulnerability and accelerated aging, as shown in the retina and by the reduced antioxidant 
capacity of aging KO mice [22,26,27]. These alterations may lead to the reduced life span and 
increased mortality (approximately twice as high as in WT mice) of mice lacking PACAP, as 
observed in our PACAP KO colony. In PACAP KO mice, mass spectrometry (MS) analysis 
uncovered an altered homeostatic protein pattern resulting in disturbed energy balance, the 
compensation of which is compromised under challenged environment and possibly during 
aging [28]. Our main hypothesis is that PACAP deficiency mimics premature aging with pre-
senile systemic degenerative changes. Here we report the result of detailed systemic 
histopathological analysis showing accelerated systemic amyloidosis in mice lacking PACAP. 
MS-based proteomic analysis of deposits identified apolipoprotein (apo)-AIV-type (Apo-AIV) 
amyloidosis with several other amyloidogenic components. All amyloid-associated proteins 
were further investigated by matrix-assisted laser desorption-ionization (MALDI) imaging MS 
(IMS) to directly map distribution of corresponding peptides in tissue. 
 
Materials and Methods 
 
Animals 
Generation of KO mice on CD1 background has been described previously [29]. Maintenance, 
backcrossing for 10 generations of the in-house-bred KO mice and all procedures were 
performed with permissions (BA02/2000-24/2011; BA02/2000-20/2006[29,30]). WT (n=29), 
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and homozygous PACAP KO mice (n=29) were grouped into 3–12- (young) and 13–24-month-
old (aging) groups. Genotyping from tail samples was performed at sacrifice using Phire Animal 
Tissue Direct PCR Kit (Thermo Fisher Scientific, Waltham, MA, USA) [30,31]. 
 
Histological analysis 
Mice (n=15 WT, 15 KO) were killed under isoflurane anesthesia (AErrane, Baxter, Budapest, 
Hungary) and removed organs (see supplementary material, Supplementary materials and 
methods for a detailed list) were placed in 4% buffered paraformaldehyde, embedded in paraffin 
wax and 3-µm-thick sections cut and stained with hematoxylin and eosin (Paraform Sectionable 
Cassette System, Tissue-Tek X-Press, AutoTek120 and Prisma Film Coverslipper HQ, smart 
automation system - Sakura Finetek, Netherlands). Parallel sections were stained with Congo 
red, the gold-standard for amyloid fibrils [31], which displayed amyloid deposits in red-orange 
under normal light, whereas apple-green birefringence was indicative of amyloid under 
polarized light. A semi-quantitative scoring of Congo red-positive deposits from 0–3 was 
performed according to pathological criteria [32,33]. Amyloid index 0: no amyloid; 1: slight 
focal; 2: moderate/severe focal or slight diffuse; 3: massive diffuse amyloid deposit. As no 
gender differences were observed, scores are presented combined [32]. Percentages of affected 
individuals for each organ were also evaluated. Statistical comparison between WT and KO 
mice was made with non-parametric Mann-Whitney test. For comparison between age groups, 
Kruskal-Wallis test and Dunn's Multiple Comparison Test were used.  
 
 
Laser microdissection (LMD)-based microproteomic analysis 
Sections of intestinal villi with massive amyloidosis were chosen for (LMD)-based 
microproteomic analysis to characterize the type of amyloidosis. Characterization was made 
using a recently developed method for proteomic analysis of small laser-microdissected 
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formalin-fixed paraffin-embedded (FFPE) samples [34,35,36]. The procedure for LMD-based 
microproteomics was described previously [37] and uses in-solution tryptic digestion of proteins 
directly from tissue pieces. The released peptides are then separated by reverse-phase liquid 
chromatography directly bridged to a Quadrupole-orbitrap mass spectrometer (see 
supplementary material, Supplementary materials and methods for details).  MaxQuant version 
1.5.2.8 was used for raw file analysis. 
 
MALDI IMS  
Intestine was selected as it contained abundant deposits in well-circumscribed areas in the villi. 
Five-µm sections were cut from two different FFPE specimens and mounted onto conductive 
indium tin oxide(ITO)-coated glass slides (Bruker Daltonik, Bremen, Germany).  
Sample processing consisted of deparaffinization of the tissue sections, antigen retrieval, on-
tissue spraying of trypsin and tissue digestion, and finally matrix deposition (see supplementary 
material, Supplementary materials and methods for details).  
MS measurements were carried out using a rapifleX MALDI Tissuetyper (Bruker Daltonik) 
instrument at 50 μm spatial resolution from m/z 640 to m/z 3000. External calibration was 
performed using Peptide calibration standard II (Bruker Daltonik). FlexImaging 5.0 (Bruker 
Daltonik) was used to visualize ion images, all displayed intensities were normalized to total ion 
count (TIC). Further data analysis was performed with SCiLS Lab 2016b software (SCiLS, 
Bremen, Germany). 
 
Immunohistochemistry for Apo-AIV and molecular analysis 
We performed immunostaining using an anti-Apo-AIV antibody (1:200, catalog number NBP1-
06019; Novus Biologicals, Littleton, CO, USA) to confirm the presence of Apo-AIV, the main 
amyloid component, in tissues with abundant deposits: intestine, kidney, liver and spleen. 
Staining was performed using a Ventana BenchMark XT Ultra (Ventana Medical Systems, Inc., 
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Tucson, AZ, USA). A method control was performed by omitting the primary antiserum, and 
which produced no staining. PCR for amyloid protein mRNAs was performed from intestinal 
samples from aging WT and KO mice (n=3/group) with confirmed amyloidosis. In addition, 
kidney homogenates (n=4/group) were processed for cytokine array analysis (Proteome Profiler 
Mouse Cytokine Array Kit, Panel A, R&D System, Minneapolis, MN, USA), according to the 
manufacturer’s instructions. Statistical analysis was performed using 2-way ANOVA followed 
by Fisher’s post hoc test. The sequences of primer pairs are given in supplementary material, 
Table S1 and further details of PCR in supplementary material, Supplementary materials and 
methods.  
 
Laboratory analyses of serum and blood 
Blood was collected from young and aging WT and KO mice (n=7/each group) under isoflurane 
overdose into BD Vacutainer tubes with sodium heparin for serum analysis or EDTA for routine 
complete blood count (Becton, Dickinson and Company, NJ, USA) Na+ and K+ ions, alkaline 
phosphatase (ALP), creatinine, cholesterol, triglyceride, high- and low-density lipoprotein 
(HDL, LDL) were measured with COBAS 8000 analyzer, (Roche Ltd, Rotkreuz, Switzerland), 
while blood count with Sysmex XN-1000-V Multispecies Hematology Analyzer (Sysmex 
Hungaria, Budapest, Hungary). Statistical analysis of serum parameters and blood count was 
performed using 2-way ANOVA followed by Fisher’s or Bonferroni’s post hoc test, 
respectively. 
 
 
Results 
 
Histopathological evaluation 
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Analysis of peripheral organs revealed more diffuse and more severe amyloidosis in the KO 
animals with progressive aging. First, we analyzed the number of animals with amyloidosis 
(Table 1). Signs in most organs had already appeared at 6 months in KO mice, whereas deposits 
appeared in WT animals typically at 15 months. The percentage of animals with deposits was 
markedly higher in KO groups than their age-matched WT mates. In WT mice most severe 
deposits were observed in organs that showed some amyloidosis already at young ages, such as 
skin and intestines. In aging KO mice, liver, spleen, intestines and thyroid gland were positive in 
all animals. Amyloid distribution in different organs is described below. Distribution of deposits 
was similar in both groups in general, with differences in time of appearance and quantity. 
Altogether, amyloidosis manifested evidently earlier, progressed more rapidly with a higher 
degree of severity in older ages and affected more KO individuals.  
 Gastrointestinal tract 
Esophageal lamina propria contained wide, filamentous, compact deposits in linear distribution. 
In the stomach, mostly the interglandular connective tissue and vessels were affected (Figure 
1A:A,B). Small intestinal villi showed highest levels of deposits in the lamina propria and vessel 
walls, and interglandular connective tissue in small and large intestine was filled in severe cases 
with aging (Figure 1A:C-F). Salivary glands were unaffected, only occasional perivascular 
tissues and vessel walls were involved. In the liver, perivascular deposits were around portal 
vessels and central vein. In sinusoidal walls, homogenous amyloid deposits were seen around 
central veins (Figure 1B:A). Patches of degenerated hepatocytes were observed in KO mice, in 
contrast to WT mice, where only single cells were affected distal from central veins. Scattered 
degenerating hepatocytes, closely associated with deposits, were surrounded by amyloid-
containing macrophages. Intramural vascular deposits were found in the pancreas in a few 
animals (Figure 1B:B), and periductal connective tissue septa were affected, but islets, exocrine 
acini or the gallbladder were unaffected.  
 Respiratory tract 
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In trachea and larynx, amyloid was deposited in vessel walls. Under the parietal pleura, discrete, 
focal deposits were observed in the lung, and intraparenchymal vessels contained amyloid. 
Alveolar cells and bronchial respiratory epithelium were unaffected.  
 Urogenital system 
Deposits mainly affected kidney glomeruli, 90% were damaged by the amorphous deposits in 
severe cases in older KO animals, while amyloid was missing from tubules or interstitium 
(Figure 1B:C-E). No deposits were found in the uterus, vagina or ovaries of female mice or in 
the testis, epididymis or seminal vesicles in males, only in peritesticular venous vessel walls. 
 Musculoskeletal and cardiovascular system 
In the skeletal muscle, small endomysial vessels were positive using Congo red. Joints or bones 
were unaffected. In the cardiac muscle, sub-endocardial deposits were occasionally observed. In 
larger arteries and veins, deposits were mainly present both intramurally and perivascularly. 
 Immune system and skin 
Only a few small patches were observed in WT spleens. Approximately 10% of the spleen was 
involved, without affecting the basic structure in young KO mice, while in older ages, 
approximately 65-70% of the spleen parenchyma was replaced by amyloid deposits in severe 
cases (Figure 1C:A,B). Deposits were seen in white and red pulps, and the sinusoid wall was 
infiltrated. Lymph nodes did not display positive deposits, only perinodular vessels contained 
some amyloid. No deposits were found in the thymus. In the skin, the main location of the 
deposits was the dermal papillary layer, continuous with the homogenous mass in the connective 
tissue surrounding appendages (hair follicles, sebaceous and sweat glands) and vessel walls 
(Figure 1C:C,D).  
 Endocrine glands and nervous system 
Diffuse deposits were observed surrounding thyroid follicles, which themselves were free of 
deposits, but were often atrophic, resulting in fibrotic transformation of the parenchyma (Figure 
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1C:E,F). Other glands (adrenal, parathyroid, pituitary) displayed no positivity, similarly to the 
CNS, peripheral nerves or eye (cornea, choroid layer, retina, sclera). 
 In several additional organs, perivascular connective tissue displayed some positivity. In 
addition, brown adipose tissue, typically present in mice in larger amounts, displayed deposits 
mainly in the connective tissue between adipocytes. In other organs only sporadic, vessel wall-
related amyloid deposits were occasionally observed (Figure 1B:F).  
 Statistical analysis of the amyloid index revealed significant overall effect of PACAP in 
spleen, esophagus, kidney, liver, thyroid gland, trachea and skin (Figure 2A). Amyloid index in 
young and older age groups also revealed significant differences between WT and KO groups. 
In most organs, severity of amyloidosis was similar in aging WT and young KO mice, showing 
that amyloidosis reached senile levels already at young ages in lack of PACAP (Figure 2B). 
Altogether, these data show that PACAP deficiency accelerates appearance of senile systemic 
amyloidosis, resulting in pre-senile degeneration with more generalized and more severe 
amyloid deposition. 
 
LMD-based microproteomic analysis 
LMD-based microproteomic analysis of amyloid deposits allowed confident identification of 
13235 peptides, corresponding to 2172 proteins. Fifteen known amyloidosis-associated proteins 
were identified [10]. These were, by order of intensity (Figure 3): Apo-AIV, Apo-E, serum 
amyloid P-component, Apo-AI, Apo-AII, transforming growth factor-beta-induced protein ig-
h3, gelsolin, Ig alpha chain C region, Ig kappa chain C region, Ig gamma-1 chain C region, 
serum amyloid A-1 protein, transthyretin, beta-2-microglobulin, lysozyme C-1, Ig gamma-3 
chain C region (gene symbols: Apoa4, Apoe, Apcs, Apoa1, Apoa2, Tgfbi, Gsn, Igha, Ighg1, 
Saa1, Trt, B2m, Lyz1, Ighg3, respectively). The most abundant proteins were Apoa4, Apoe, 
Apcs and Apoa1. 
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MALDI IMS-correlation with LMD-based microproteomic dataset 
Sections with Congo red-positive areas were examined under polarized light with digitally 
marked representative regions superimposed with MALDI data, and spectra profiles were 
compared between negative and positive areas in order to find discriminant peaks (Figure 4, 
supplementary material, Figure S1). Peptide m/z values obtained from MALDI MSI were 
compared to peptides identified by LC-MS/MS to attribute IDs. We found 11 peptides identified 
by LC-MS/MS matching m/z values detected in deposits by MALDI IMS. Six peptides were 
assigned to Apoe, four to Apoa4, one to Apoa1, and one to Apoa2. To evaluate the difference of 
all m/z peptide values through the two regions, the Receiver Operating Characteristic (ROC) test 
was performed and the area under the ROC curve (AUC) measured was >0.9 for all peptides 
except for m/z 1239.7 and 1743.9 where the AUC was >0.7.  
 
Immunohistochemistry for Apo-AIV and molecular analysis  
As Apoa4 was identified as the main amyloidosis-related protein in the deposits by LC-MS/MS, 
we confirmed the presence of this apolipoprotein by immunohistochemistry in the organs where 
most massive amyloidosis was found. We found Apo-AIV positive areas in the examined organs 
corresponding to the distribution of Congo red-positive regions in aging animals (Figure 1D). In 
KO mice, Apo-AIV immunopositivity was stronger and more widespread than in WT mice, in 
accordance with the histopathological observations.  
The balance in the expression of mRNA encoding amyloid specific proteins identified with MS 
in the intestine was disturbed in absence of PACAP, with some showing stronger, while others 
weaker expression in the KO samples than in the WT ones (supplementary material, Figure S2). 
Results of the cytokine array revealed dramatically increased levels of several cytokines in the 
aging KO samples than in other groups. Of those, most marked changes were observed in BLC 
(B lymphocyte chemoattractant), IL-1ra (interleukin-1 receptor antagonist) and RANTES 
(regulated on activation, normal T cell expressed and secreted) (Figure 5).  
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Serum and blood analyses 
Serum analysis revealed no difference in Na+ or K+ levels. Among the parameters referring to 
liver and kidney functional deficit, ALP and creatinine were examined, respectively. While there 
was no difference in ALP levels, serum creatinine levels showed a marked, significant increase 
in aging versus young PACAP KO mice in contrast to WT animals, where there was no age-
related increase. Lipid parameters (HDL, LDL, total cholesterol) showed slight, but not 
statistically significant increases in aging PACAP KO animals (supplementary material, Figure 
S3). The complete blood count showed no significant alterations between the examined groups. 
 
Discussion 
The increased vulnerability to stressors of animals lacking PACAP and its well-known 
cytoprotective effects support the hypothesis that PACAP deficiency mimics aspects of age-
related pathophysiological changes. Here we described premature appearance of severe senile 
systemic amyloidosis in mice lacking endogenous PACAP. We showed with mass 
spectrometry–based proteomic analysis, confirmed by immunohistochemistry, that 
apolipoprotein-AIV was the main amyloid protein in the deposits with several accompanying 
ones. These findings indicate that in the absence of endogenous PACAP accelerated age-related 
degenerative changes occur, pointing to the important role of PACAP in aging-induced systemic 
processes. 
It is still not entirely understood why deposits are formed in older age and why only in 
some tissues [38]. Several animal models have been proposed to study age-related systemic 
amyloidosis, since spontaneous amyloidosis is long known to occur in various strains of inbred 
mice [39]. A study in different mice [5] described spontaneous systemic senile amyloidosis in 
75% of strains. This was confirmed in a 15-year survey, where higher incidence of amyloidosis 
was found in CD1 mice compared to others [40]. In our CD1 mice, we found no deposits during 
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the first year in WTs (only in sporadic skin and intestinal spots), but already at early ages in 
some PACAP KO individuals. Our results, showing a few individuals with slight amyloidosis at 
6 months, are also in accordance with the description of spontaneous amyloidosis in aging 
inbred mice [8]. The observation that the degree of fibril formation showed no gender difference 
is also in agreement with earlier findings of CD1 and other strains [33,40,41]. Here we 
described a type of age-related systemic amyloidosis with mainly kidney, spleen, liver, skin, 
thyroid, intestine, stomach, trachea and esophagus involvement. The severe kidney involvement 
is also reflected in higher creatinine levels, indicating functional disturbance. While most forms 
of systemic amyloidosis affect joints and periarticular tissues [42], we did not observe articular 
amyloid deposits. Our observation that CNS and peripheral nerves lacked deposits is in accord 
with earlier findings in systemic amyloidosis [8,43,44].  
It is now known that amyloid deposits contain several distinct main and accompanying 
minor components[10,45] that can be structurally unrelated, and can be deposited in different 
locations in conglomerates or in distinct foci [46,47]. Proteomic approaches have identified the 
composition of the deposits [5,48-53], with Apoe, serum amyloid P component, and Apoa4 and 
Apoa1 present in almost all amyloidosis types as incorporated proteins [10]. Of these, the first 3 
are considered specific amyloidosis biomarkers. We used LC-MS/MS-based proteomics, 
adequate for the identification of amyloidosis-associated proteins and the subsequent 
classification of amyloidosis subtypes [10,34,35,36,48,52,54,55]. In the present context, 
deposits could be found in large quantities within different organs. We could identify with high 
confidence 15 amyloidosis-related proteins with Apoa4 having the highest abundance [10,48]. It 
is noteworthy that non-amyloidosis-associated proteins reported in human cases of AApoAIV 
amyloidosis such as vitronectin, serum albumin, clusterin, collagen alpha-2 (I) chain, collagen 
alpha-1 (I) chain and actin [48] were also found in our samples. The combined analysis of 
LMD-based microproteomic and MALDI IMS resulted in a more comprehensive 
characterization, similarly to previous descriptions in renal biopsies [56]. By matching the 
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peptide masses identified by LC-MS/MS with MALDI IMS, eleven peptides related to Apoa4 
(n. peptides= 4), Apoe (n. peptides= 4) and Apoa1 (n. peptides=1) Apoa2 (n. peptides=1), were 
detected exclusively in amyloid regions, in excellent concordance with the Congo red-positive 
areas.  
The systemic amyloidosis-associated protein described here was predominantly Apo-
AIV, confirmed by Apo-AIV immunohistochemistry. We could also detect mRNA for the 
proteins identified by MS in the same tissues, but the balance of the different amyloidogenic 
protein mRNAs was disturbed, possibly indicating a pathological feedback for production due to 
the local deposits and/or disturbed synthesis. Apolipoproteins play a role in lipid metabolism 
and transport [57] with susceptibility to form fibrils possibly due to their intrinsic flexibility 
[46]. Considering the role of apolipoproteins in lipid metabolism, we ran a laboratory test for the 
main lipid parameters, but found no significant differences. This indicates no major disturbances 
in lipid metabolism in general, but raises the possibility of some other mechanisms leading to 
apolipoprotein deposits in KO tissues. Apolipoproteins have long been associated with fibril 
formation in cerebral and systemic amyloidosis [58]. Among apolipoproteins, Apo-AIV shows 
age-related decline (which we could also detect in KO mice), has the highest sensitivity to 
denaturation and vulnerability to environmental disturbances [46]. Recent reports, using 
proteomics-based assays, have shown a more widespread occurrence of AApoAIV amyloidosis 
than previously thought [48,50]. Apo-E can also be consistently detected in deposits [59,60] and 
Apo-AI has long been associated with systemic amyloidosis with different localizations [51,61]. 
AApoAIV and AApoE dominating systemic amyloidosis is known in inbred foxes with mainly 
kidney, spleen, oral cavity and vascular involvement [62]. Apo-AII is also known to form senile 
fibrils [33,44,63] including inbred mouse strains[8]. Serum amyloid P component, a constituent 
in all amyloid deposits [10,63,64], was also found in our samples. Although its role is 
controversial, i.e. both anti-amyloidogenic and pro-amyloidogenic effects have been described 
[65], its presence is usually attributed to its role in stabilizing the fibrils, thereby preventing 
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proteolytic degradation [66,67]. A recent study has suggested that in addition to the most 
common proteins, serum amyloid P component, Apo-E and Apo-AIV, the amyloid proteomic 
signature should also include vitronectin and clusterin, as co-deposited proteins [53]. We could 
also detect other proteins associated with amyloid formation, such as gelsolin, transthyretin, Ig 
kappa and gamma-1 chain C region, serum amyloidA1, beta2 microglobulin and lysozyme C1. 
As these proteins were detected with very low intensities, they do not seem to be major amyloid 
constituents in PACAP KO mice.  
Good animal models are important in studying diseases of protein misfolding, as it is 
still unknown why the same protein becomes fibrillogenic with age and why only in some 
tissues [38]. It has been assumed that age-related forms of amyloidosis reflect chronic 
inflammatory states, high concentrations of amyloidogenic proteins and a long latent period of 
seed formation. In our study, chronic inflammation is excluded due to lack of histological signs 
of generalized inflammation or changes in blood cell counts. However, we detected an altered 
cytokine profile, especially in aging KO mice. These data indicate a disturbed balance of pro- 
and anti-inflammatory cytokines and may lead to a shift in the cytokine profile towards a pro-
inflammatory milieu, possibly creating a more favorable microenvironment for amyloid 
deposition in mice lacking PACAP. However, the altered cytokine profile might as well be the 
consequence of amyloid deposition, leading to upregulation of both pro- and anti-inflammatory 
cytokines. Earlier studies found differences in the proteome of PACAP KO mice, also leading to 
a disturbed energy balance, which is possibly further disturbed in aging [28]. Alterations in 
cytokine expression have been described earlier in several experimental paradigms after PACAP 
treatment and has been suggested as an aggravating factor in slower regeneration capacity of 
KO mice [68,69]. 
Age-related degenerative diseases are increasing, and the problem goes far beyond the 
two best-known diseases, Alzheimer’s and Parkinson’s, with protein misfolding in the 
background [70]. PACAP levels decline with age in humans and experimental animals [71], as 
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shown in rhesus monkey and post mortem human brains of Alzheimer’s patients and in 
cognitive decline preceding the disease [22,23,72,73], with association between PACAP levels 
and disease scores. The few data available to date indicate that PACAP deficiency accelerates 
aging. Aging KO animals display higher levels of oxidative stress [26], earlier appearance of 
retinal degeneration [27] and decreased tear secretion with increased corneal keratinization [74]. 
In the present study, we describe accelerated systemic senile amyloidosis in PACAP deficient 
mice, which might indicate an early aging phenomenon in this strain. Thus, PACAP KO mice 
could serve as a model of accelerated aging, with human relevance, similarly to the widely used 
senescence-accelerated mouse, which also displays spontaneous age-associated amyloidosis 
[41,74,75]. Exogenous PACAP can compensate lack of PACAP, as shown in several acute 
injury models in KO mice. Among others, PACAP administration could reduce the toxic effects 
of ethanol or oxidative stress in cerebellar neurons [76]. Exogenous PACAP addition could also 
attenuate the increased ischemia-induced lesions in KO retinas [77]. Furthermore, Ohtaki and 
co-workers found greater infarct volume and worse behavioral deficits in hetero- and 
homozygous PACAP deficient mice than in WT ones. However, both infarct volume and 
neurological deficit scores were improved by PACAP injection [69]. Effectivity of factors 
slowing down misfolded fibril formation and their aggregation decreases, while amyloidogenic 
mechanisms are accelerated with aging, especially in case of genetic susceptibility [70,78,79]. 
Alterations in metabolic enzymes might partially account for the decreased anti-oxidant and 
detoxifying capacity of PACAP KO mice [2,28]. The disturbed balance in homeostatic 
molecules, inflammatory factors and metabolic enzymes may be compensated in young ages 
under normal conditions, while they create an unfavorable milieu for increased vulnerability in 
case of injury and aging-related processes. Several other properties of PACAP might be 
involved in cytoprotection, for example, PACAP prevents toxic amyloid-beta formation [80,81], 
rescues cells from amyloid toxicity [73,82], acts against increased apoptosis associated with 
amyloidosis [83,84] and has a unique potency to bind to negatively charged glycosaminoglycans 
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[85,86], which, in turn, co-accumulate with amyloid [87]. It is proposed that PACAP plays a 
role in the complex cellular interactions that lead to tissue destruction in amyloidosis [88] and 
that the lack of the general rejuvenating effect of PACAP accelerates amyloid formation (Figure 
6). PACAP deficient mice, with their higher vulnerability to noxious stimuli, resemble aging 
cells with vulnerability to cell death [70]. The physiological or pathological decline of PACAP 
lead to an increased susceptibility for degenerative processes in the elderly and thus, to 
accelerated age-related diseases. Our observations point to a multifaceted role of PACAP in 
aging and age-related degenerative processes and could initiate further studies on the role of 
PACAP in aging.  
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Table 1.  Percentage of animals showing signs of amyloidosis. 
Organ 
% of WT  
3-12 months 
% of WT  
13-24 months 
% of KO  
3-12 months 
% of KO  
13-24 months 
Spleen    0 67 67 100 
Esophagus    0 43 71   75 
Kidney    0 33 57   86 
Liver    0 17 29 100 
Thyroid gland    0 25 60 100 
Skin 14 67 57   88 
Intestines 10 78 56 100 
Heart    0 14 25   29 
Lung    0 33 50   63 
Stomach    0 60 43   50 
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Figure Legends 
 
Figure 1. Representative photomicrographs of amyloid deposits in tissues from PACAP 
KO mice and of Apo-AIV immunoreactivity in aged WT and PACAP KO mice. (A) 
Amyloid deposits in esophagus (A,B) and small intestine of a 16 month-old PACAP KO mouse 
(C,D), and WT of the same age (E,F). Congo-red staining without polarizing light (A,C,E) 
showing red homogenous amyloid deposits confirmed in the same locations of the same sections 
with polarizing light displaying apple-green birefringence (B,D,F). Scale bar: 200 µm (A,B) or 
170µm (C-F). 
(B) Amyloid deposits in liver (A), pancreas (B), kidney (C,D), and a vein in adipose tissue (F) 
of a 16 month-old PACAP KO mouse and in the kidney of WT of the same age (E). Congo-red 
staining without polarizing light (C,E) showing red homogenous amyloid deposits, and apple-
green birefringence under polarizing light (A,B,D,F). Insets (A,D) show an enlarged area of a 
central vein in the liver (A) and a renal glomerulus (D). Scale bar: 350µm (A), 80 µm (B,E), 
30µm (C), 100µm (D), or 200µm (F).   
(C) Amyloid deposits in spleen (A, B), skin (C,D) and thyroid gland (E,F) of a 16 month-old 
PACAP KO mouse. Congo-red staining without polarizing light (A,C,E) showing red 
homogenous deposits confirmed in the same sections with polarizing light displaying apple-
green birefringence (B,D,F). Scale bar: 250 µm (A-D) or 80µm (E,F). 
(D) Apo-AIV immunoreactivity in kidney glomeruli of aging KO (A) and aging WT (B), in 
degenerated hepatocytes in patches of an aging KO (C) or in single hepatocytes in aging WT 
mouse (D) and around the central vein in an aging KO animal (E). Intestinal villi displaying 
immunoreactivity in an aging KO mouse (F). Scale bar: 30 µm (A, B), 70 µm (C, D, E) or 150 
µm (F).  
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Figure 2. Amyloid index in young and old WT and PACAP KO mice. 
(A) Overall amyloid index in WT and PACAP KO mice in selected organs with massive 
amyloid deposits in old age. Mean±SEM, where *p<0.05; **p<0.01 versus WT mice.  
(B) Amyloid index in young (3-12 months) and aging (13-24 months) WT and PACAP KO 
mice in selected organs with massive amyloid deposits at older ages. Mean±SEM, where 
*p<0.05, **p<0.01, ***p<0.001 versus young WT mice. +p< 0.05 versus young PACAP KO 
mice.   
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Figure 3. Characterization of the type of amyloidosis using laser microdissection based 
microproteomics.  (A) Congo red-stained section of the intestine of PACAP KO mouse. The 
regions surrounded in red in the inset correspond to the laser-microdissected one from a serial 
section. (B) Intensities of amyloidosis-related proteins identified in the sample. The high 
intensity of Apoa4, Apoe, Apcs, Apoa1 suggests that the amyloidosis type is ApoA4. 
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SUPPLEMENTARY MATERIAL ONLINE 
 
Supplementary materials and methods  YES 
 
Supplementary figure legends  NO, because the legends are embedded with the Suppl 
figures 
 
 
 
Figure S1. Correlation between Congo red and the MALDI image of m/z 1228.7 from the 
mouse intestine tissue section presented in Figure 4 
 
Figure S2. Representative data of three independent RT-PCR reactions of amyloid specific 
protein mRNAs identified with mass spectrometry of aging WT and KO mice 
 
Figure S3. Main laboratory serum parameters in young and old WT and PACAP KO mice 
 
Table S1. Nucleotide sequences, amplification sites, GenBank accession numbers, amplimer 
sizes and PCR reaction conditions for each mouse primer pair are shown 
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